OakChart

Conexeu Sciences Inc

CNXUHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:58 PM ET

2.26+0.04 (1.80%)
2026-11-12 06:57 CET
Market cap
69.68 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-13.63 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.54
P/E
-
Compare

Price

CNXU against its 20 and 50-day averages
2050earnings
Patternshover a marker to name it
5.0010.0015.00575K1.1MVolumeMay 26Jul 26Aug 26Sep 26Oct 26Nov 26CNXUclose 2.2620-day 2.7750-day 3.612.2652w high

88.0% under the 52-week high of 18.79 on 3 Jun 2026. 52-week low 2.01 on 10 Nov 2026. Last 15 sessions, 71.6% high to low

Volume 0.84× normal · the line is the 50-bar volume average

Profile

CNXU
52-week range, 1% of the way up
2.0118.79

Conexeu Sciences, Inc. engages in the development of regenerative biomaterials needed in wound care, dentistry, and aesthetics. The company was founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell on November 2, 2022 and is headquartered in Reno, NV.

Employees4
IPOMay 21, 2026
ATR, 14d0.37
Rel volume0.84
Short float3.50%
Insider own60.17%
Inst own7.58%

Snapshot

6 groups

Valuation

Index-
Market Cap69.67M
Enterprise Value67.53M
Income-13.63M
Sales0.00M
Book/sh0.21
Cash/sh0.07
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees4
IPOMay 21, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B10.58
P/C31.53
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.31
Current Ratio5.31
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.54
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-950.49% -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-1549.12%
Sales Q/Q-
EarningsJul 01
EPS/Sales Surpr.0.00% -

Ownership

Insider Own60.17%
Insider Trans2.03%
Inst Own7.58%
Inst Trans78.13%
ROA-
ROE-
ROIC-231.59%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-18.34%
SMA50-37.39%
SMA200-70.11%
Trades-

Technical

Shs Outstand27.40M
Shs Float12.28M
Short Float3.50%
Short Ratio1.50
Short Interest0.43M
52W High18.79 -87.97%
52W Low2.01 12.44%
Volatility11.34% 14.31%
ATR (14)0.37
RSI (14)34.30
Beta-
Rel Volume0.84
Avg Volume286.81K
Volume240,437

Performance

Perf Week1.80%
Perf Month-31.72%
Perf Quarter-71.64%
Perf Half Y-
Perf YTD-83.26%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price20.00
Prev Close2.22
Price2.26
Change %1.80%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Jun 22, 2026InitiatedHH.C. WainwrightBuy$20+785.0%

Peers

Mkt cap
TickerCompanyMkt cap
MDXGMimedx Group Inc484.47M
CLGNCollPlant Biotechnologies Ltd7.48M
HUMAHumacyte Inc164.37M
ORGOOrganogenesis Holdings Inc136.29M
ELUTElutia Inc40.75M
SMTISanara MedTech Inc290.43M
TELATELA Bio Inc42.51M
RCELAVITA Medical Inc429.73M
IARTIntegra Lifesciences Holdings Corp1.15B
ESTAEstablishment Labs Holdings Inc2.11B

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Purcell Lynn SebastianDirectorOct 15 '26Buy3.00166,666499,9983,118,514Oct 19 04:46 PM
Bogart David RobertChief Commercial OfficerSep 25 '26Option Exercise0.00750,0007501,812,500Sep 28 05:38 PM
Sharpe Jeffrey NathanDirectorSep 14 '26Option Exercise0.00500,0005001,500,000Sep 15 04:30 PM
Purcell Lynn SebastianDirectorJun 18 '26Buy0.80202,500162,0002,734,240Jun 23 08:15 PM
Wright Michael G.10% OwnerJun 18 '26Option Exercise0.00250,0002502,148,048Jun 22 01:25 PM
Wright Michael G.10% OwnerMay 26 '26Option Exercise0.00400,0004001,898,048May 28 11:39 AM
Sharpe Jeffrey NathanDirectorMay 22 '26Option Exercise0.00500,0005001,000,000May 26 06:16 AM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B

News

latest 14 of 44
  • Conexeu Sciences Launches Human Collagen Initiative for Regenerative Aesthetics as GLP-1 Drives Demand for Tissue Restoration (GlobeNewswire)
  • Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors (GlobeNewswire) +8.37% -22.53%
  • Conexeu Sciences Advances Ten Minute Tissue Toward Planned FDA 510(k) Submission (GlobeNewswire) +17.31%
  • A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture (PR Newswire) -18.19%
  • Conexeu Sciences Sets September and October 2026 Conference Schedule (GlobeNewswire)
  • Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration (GlobeNewswire)
  • Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration (GlobeNewswire)
  • Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison (Ipo Edge) -6.62%
  • The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It. (PR Newswire) +17.68%
  • The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It (GlobeNewswire) -8.12%
  • One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics (PR Newswire)
  • A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It (PR Newswire) -12.13%
  • A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill (GlobeNewswire)
  • Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-07-01-0.110-0.110-0.0860.000.001
2026Q12026-04-01-0.090--0.0820.00--
2026Q3---0.100--0.001
2026Q4---0.110--0.001
2027Q1---0.120--0.001
2027Q2---0.130--0.001
2027Q3---0.140--0.001
2027Q4---0.150--0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-07-011000.000.000.00
2026Q3S2026-06-181000.000.000.00
2026Q3E2026-07-01100-0.10-0.10-0.10
2026Q3E2026-06-18100-0.10-0.10-0.10
2026Q2S2026-06-181000.000.000.00
2026Q2E2026-06-18100-0.11-0.11-0.11

Estimate history

EPS, annual-0.002-0.023-0.188-0.54
Period202320242025TTM
EPS, quarterly-0.005-0.014-0.017-0.09-0.082-0.086-0.282
PeriodQ4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000
Period202320242025TTM
Sales, quarterly0000000
PeriodQ4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual20.91620.91620.91627.397
Period202320242025MRQ
Shares, quarterly20.91620.91626.75820.91620.91626.75827.397
PeriodQ4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Total Revenue0.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.020.000.00
Gross Profit-0.03-0.020.000.00
Selling, General and Administrative Excl. Other13.813.940.640.04
Research and Development1.940.480.280.00
Other Operating Expense0.000.000.000.00
Operating Income-13.84-3.96-0.64-0.04
Interest Expense0.010.010.020.00
Unusual Expense0.07-0.04-0.180.00
Net Income Before Taxes-13.63-3.92-0.47-0.04
Income Taxes0.000.000.000.00
Consolidated Net Income-13.63-3.92-0.47-0.04
Net Income From Continuing Operations-13.63-3.92-0.47-0.04
Net Income-13.63-3.92-0.47-0.04
EPS (Recurring)-0.50-0.19-0.03-0.00
EPS (Basic, Before Extraordinaries)-0.54-0.19-0.02-0.00
EPS (Diluted)-0.54-0.19-0.02-0.00
EBITDA-13.81-3.94-0.64-0.04
Non-Operating Income (Expense)0.110.000.010.00
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense-0.24--
Shares Outstanding27.4020.9220.9220.92
Market Capitalization69.6869.68--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.010.000.000.00
Gross Profit-0.01-0.01-0.01-0.01-0.00-0.000.00
Selling, General and Administrative Excl. Other7.672.371.712.050.450.330.24
Research and Development1.500.150.160.130.100.060.24
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-7.68-2.38-1.72-2.06-0.46-0.33-0.24
Interest Expense0.000.000.000.000.000.000.00
Unusual Expense0.070.000.000.000.00-0.04-0.12
Net Income Before Taxes-7.73-2.30-1.72-1.88-0.46-0.29-0.11
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-7.73-2.30-1.72-1.88-0.46-0.29-0.11
Net Income From Continuing Operations-7.73-2.30-1.72-1.88-0.46-0.29-0.11
Net Income-7.73-2.30-1.72-1.88-0.46-0.29-0.11
EPS (Recurring)-0.28-0.09-0.08-0.09-0.02-0.02-0.01
EPS (Basic, Before Extraordinaries)-0.28-0.09-0.08-0.09-0.02-0.01-0.01
EPS (Diluted)-0.28-0.09-0.08-0.09-0.02-0.01-0.01
EBITDA-7.67-2.37-1.71-2.05-0.45-0.33-0.24
Non-Operating Income (Expense)0.040.080.00-0.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense1.040.260.19-0.060.00-
Shares Outstanding27.4026.7620.9220.9226.7620.9220.92
Market Capitalization69.68236.28-----

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY
Cash & Short Term Investments4.830.310.00
Short Term Receivables2.070.000.00
Inventories0.000.000.00
Other Current Assets0.550.030.00
Total Current Assets7.460.350.00
Net Property, Plant & Equipment0.010.000.00
Total Investments and Advances0.000.000.00
Intangible Assets0.180.190.00
Other Assets0.040.000.00
Total Assets7.690.530.00
Short Term Debt Incl. Current Port. of LT Debt0.000.000.00
Accounts Payable0.000.000.00
Other Current Liabilities0.340.340.04
Total Current Liabilities0.340.340.04
Long Term Debt0.000.100.00
Provision for Risks Charges0.000.000.00
Other Liabilities0.000.000.00
Total Liabilities0.340.440.04
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value0.000.000.00
Common Equity7.350.09-0.04
Total Shareholders Equity7.350.09-0.04
Accumulated Minority Interest0.000.000.00
Total Equity7.350.09-0.04
Total Liabilities & Stockholders Equity7.690.530.00
Book Value Per Share0.350.00-0.00
Tangible Book Value Per Share0.34-0.00-0.00
Full-Time Employees44-
Price to Book Ratio10.58--
Return on Assets-95.43-176.75-
Return on Equity-105.36-1,586.24-
Return on Invested Capital-53.36-244.39-
Quick Ratio22.201.020.00
Current Ratio22.201.020.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Net Income--3.92-0.47-0.04
Depreciation-0.02--
Deferred Taxes & Investment Tax Credit-0.000.000.00
Other Funds (Non Cash)-2.14-0.180.00
Funds from Operations--1.77-0.65-0.04
Extraordinary Item-0.000.000.00
Changes in Working Capital-0.100.420.03
Cash from Operating Activities--1.67-0.23-0.00
Capital Expenditures--0.020.000.00
Net Assets From Acquisitions-0.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.00
Purchase or Sale of Investments-0.000.000.00
Purchase of Investments-0.000.000.00
Sale Or Maturity of Investments-0.000.000.00
Other Uses--0.070.000.00
Other Sources-0.000.000.00
Cash from Investing Activities--0.090.000.00
Cash Dividends Paid-0.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.00
Change in Capital Stock-6.420.530.00
Repurchase of Common Pref Stock-0.000.000.00
Sale of Common Pref Stock-6.420.530.00
Proceedsfrom Stock Options-6.420.530.00
Issuance or Reduction of Debt, Net--0.090.000.00
Change in Long Term Debt--0.090.000.00
Issuance of Long Term Debt-0.000.000.00
Reduction of Long Term Debt--0.090.000.00
Net Financing Active Other Cash Flow--0.050.000.00
Other Financing Activities Uses--0.05--
Cash from Financing Activities-6.280.530.00
Exchange Rate Effect--0.000.010.00
Net Change in Cash-4.520.310.00
Free Cash Flow--1.69-0.23-0.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q22025Q1
Cash & Short Term Investments2.217.306.714.83--
Short Term Receivables0.000.000.072.07--
Inventories0.000.000.000.00--
Other Current Assets4.540.610.680.55--
Total Current Assets6.767.917.467.46--
Net Property, Plant & Equipment0.150.040.010.01--
Total Investments and Advances0.070.070.000.00--
Intangible Assets0.160.160.170.18--
Other Assets0.020.010.060.04--
Total Assets7.168.207.707.69--
Short Term Debt Incl. Current Port. of LT Debt0.040.000.000.00--
Accounts Payable0.000.000.000.00--
Other Current Liabilities1.231.000.880.34--
Total Current Liabilities1.271.000.880.34--
Long Term Debt0.030.000.000.00--
Provision for Risks Charges0.000.000.000.00--
Other Liabilities0.000.000.000.00--
Total Liabilities1.311.000.880.34--
Non-Equity Reserves0.000.000.000.00--
Preferred Stock - Carrying Value0.000.000.000.00--
Common Equity5.857.206.837.35--
Total Shareholders Equity5.857.206.837.35--
Accumulated Minority Interest0.000.000.000.00--
Total Equity5.857.206.837.35--
Total Liabilities & Stockholders Equity7.168.207.707.69--
Book Value Per Share0.210.270.330.35--
Tangible Book Value Per Share0.210.260.320.34--
Full-Time Employees--44--
Price to Book Ratio10.5832.83----
Return on Invested Capital-131.31-32.02-25.18-25.53--
Quick Ratio5.317.898.5122.20--
Current Ratio5.317.898.5122.20--

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q22025Q1
Net Income-7.73-2.30-1.72--0.46-0.29
Depreciation0.010.010.01-0.000.00
Other Funds (Non Cash)4.160.310.19--0.000.05
Funds from Operations-3.56-1.99-1.52--0.46-0.24
Extraordinary Item0.000.000.00-0.000.00
Changes in Working Capital-3.200.18-0.01-0.030.00
Cash from Operating Activities-6.76-1.80-1.54--0.43-0.24
Capital Expenditures-0.04-0.03-0.00--0.00-0.01
Net Assets From Acquisitions0.000.000.00-0.000.00
Sale of Fixed Assets and Businesses0.000.000.00-0.000.00
Purchase or Sale of Investments0.000.000.00-0.000.00
Purchase of Investments0.000.000.00-0.000.00
Sale Or Maturity of Investments0.000.000.00-0.000.00
Other Uses0.00-2E-060.00-0.000.00
Other Sources0.000.000.00-0.000.00
Cash from Investing Activities-0.04-0.03-0.00--0.00-0.01
Cash Dividends Paid0.000.000.00-0.000.00
Preferred Dividends (Cash Flow)0.000.000.00-0.000.00
Change in Capital Stock1.832.433.42-0.000.55
Repurchase of Common Pref Stock0.000.000.00-0.000.00
Sale of Common Pref Stock1.832.433.42-0.000.55
Proceedsfrom Stock Options-0.472.432.99-0.000.55
Issuance or Reduction of Debt, Net0.000.000.00--0.100.00
Change in Long Term Debt0.000.000.00--0.100.00
Issuance of Long Term Debt0.000.000.00-0.000.00
Reduction of Long Term Debt0.000.000.00--0.100.00
Net Financing Active Other Cash Flow-0.120.000.00--0.000.00
Other Financing Activities Uses-0.120.000.00--0.000.00
Cash from Financing Activities1.702.433.42--0.100.55
Exchange Rate Effect--0.00---0.00
Net Change in Cash-5.100.591.88--0.530.30
Free Cash Flow-6.80-1.83-1.54--0.43-0.25

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.50%0.4M12.3M280.02K
2026-10-152.64%0.3M11.2M234.07K
2026-09-302.60%0.2M8.1M199.44K
2026-09-151.94%0.2M8.9M173.61K
2026-08-312.22%0.2M9.1M156.87K
2026-08-141.15%0.1M11.3M114.61K
2026-07-311.31%0.1M11.3M105.10K
2026-07-151.52%0.2M11.3M100.77K
2026-06-300.36%0.0M10.3M79.57K
2026-06-150.23%0.0M11.3M93.36K
2026-05-290.28%0.0M7.6M47.63K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05DNotice of sales of securities on Form D (Regulation D)SEC
2026-11-05DNotice of sales of securities on Form D (Regulation D)SEC
2026-10-29424B3SEC
2026-10-278-KCurrent report2026-10-21SEC
2026-10-21DNotice of sales of securities on Form D (Regulation D)SEC
2026-10-21424B3SEC
2026-10-208-KCurrent report2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-09-29DNotice of sales of securities on Form D (Regulation D)SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-15DNotice of sales of securities on Form D (Regulation D)SEC
2026-09-15SCHEDULE 13D/ASEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-15424B3SEC
2026-09-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-07-31SEC
2026-09-10424B3SEC
2026-09-108-KCurrent report2026-09-04SEC
2026-09-094/A2026-09-04SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-04SCHEDULE 13G/ASEC
2026-09-04SCHEDULE 13GSEC
2026-08-31DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-18SCHEDULE 13DSEC
2026-08-18SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-07-31DNotice of sales of securities on Form D (Regulation D)SEC
2026-07-28SCHEDULE 13GSEC
2026-07-20SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10500.00K100
2026-090000
2026-080000
2026-070000
2026-06162.00K100
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
GEODE CAPITAL MANAGEMENT, LLC0.53%
UBS Group AG0.18%
Jefferies Financial Group Inc.0.04%
MORGAN STANLEY0.02%
CITIGROUP INC0.02%
HOLLENCREST CAPITAL MANAGEMENT0.00%
Paladin Partners, LLC0.00%
ROYAL BANK OF CANADA0.00%
Colonial Trust Advisors0.00%
Farther Finance Advisors, LLC0.00%

Funds

Fund% owned
-

OakChart. CNXU. Cached 15 minutes.